united states , fail to either complete treatment or show a long-term sustained response to therapy . as a result , we believe new safe and effective treatment options for hcv infection are needed . telaprevir development program we are conducting three major phase 2b clinical trials of telaprevir . prove 1 is ongoing in the united states and prove 2 is ongoing in european union , both in treatment-na efve patients . prove 3 has commenced and is being conducted with patients in north america and the european union who did not achieve sustained viral response with previous interferon-based treatments . prove 1 and prove 2 are fully enrolled , and we commenced patient enrollment in prove 3 in january 2007 . prove 1 and prove 2 we expect that together , the prove 1 and prove 2 clinical trials will evaluate rates of sustained viral response , or svr , in approximately 580 treatment-na efve patients infected with genotype 1 hcv , including patients who will receive telaprevir and patients in the control arms . svr is defined as undetectable viral levels 24 weeks after all treatment has ceased . a description of each of the clinical trial arms for the prove 1 and prove 2 clinical trials , including the intended number of patients in each trial , is set forth in the following table : the prove 1 and prove 2 clinical trials together have the following four key objectives : 2022 to evaluate the optimal svr rate that can be achieved with telaprevir therapy in combination with peg-ifn and rbv ; 2022 to evaluate the optimal treatment duration for telaprevir combination therapy ; 2022 to evaluate the role of rbv in telaprevir-based therapy ; and 2022 to evaluate the safety of telaprevir in combination with peg-ifn and rbv . in the prove 1 and prove 2 clinical trials , patients receive telaprevir in a tablet formulation at a dose of 750 mg every eight hours for 12 weeks . the prove 1 clinical trial is double-blinded and placebo-controlled , and the prove 2 clinical trial is partially-blinded and placebo-controlled . in december 2006 , we announced results from a planned interim safety and antiviral activity analysis that was conducted and reviewed by the independent data monitoring committee overseeing the prove 1 clinical trial . as of the cut-off date of the interim analysis , a total of 250 patients had been enrolled in the prove 1 clinical trial and received at least one dose of telaprevir or placebo . in the data reported , the patients in all three telaprevir-containing arms ( approximately 175 patients ) were pooled together and the results were compared to the results in the control arm of peg-ifn and rbv and placebo ( approximately 75 patients ) . at the time of the data cut-off for the safety analysis , approximately 100 patients had completed 12 weeks on-study and more than 200 patients had completed eight weeks . the most common adverse treatment regimen number of patients ( treatment na efve ) prove 1 number of patients ( treatment na efve ) prove 2 total .

Table:
treatment regimen | number of patients ( treatment na efve ) prove 1 | number of patients ( treatment na efve ) prove 2 | total
12-week regimens of telaprevir in combination with peg-ifn and rbv | 20 | 80 | 100
12-week regimens of telaprevir in combination with only peg-ifn | 0 | 80 | 80
12-week regimens of telaprevir in combination with peg-ifn and rbv followed by 12 weeks of therapy with peg-ifn and rbv | 80 | 80 | 160
12-week regimens of telaprevir in combination with peg-ifn and rbv followed by 36 weeks of therapy with peg-ifn and rbv | 80 | 0 | 80
48-weeks of therapy with peg-ifn and rbv | 80 | 80 | 160
total | 260 | 320 | 580
.

Question: what was the percent of the total treatment regiment for prove1 for the 48-weeks of therapy with peg-ifn and rbv
Answer: 30.8%
Calculation: divide(80, 260)